Myriad RBM

Rules-Based Medicine (RBM) was a spinoff of Luminex. It was said at the time that if we developed such great technology then we needed great content. RBM began developing commercial immunoassay service offerings on the instrument the Luminex founders developed. We began collaborating with major pharmaceutical companies such as Merck, Pfizer, Sanofi and Roche to develop biomarker tests utilized in clinical trial research for indications including oncology, diabetes and immunoncology. The aim was for the Pharma companies to develop drugs and to use the Luminex platform to monitor safety and efficacy of the drugs being tested in clinical trials by providing the highest quality, reliable, reproducible biomarker data in a consumable format through the testing of biological samples. RBM was acquired by Myriad Genetics in 2011 for $80MM in cash. After the acquisition I rebranded Myriad RBM to align with Myriad Genetics’ brand standards. As creative director I helped implement high quality videos, brochures, advertisements, websites, white papers and reports for pharmaceutical researchers.

Strategic and tactical marketing including channels, ad development and placement
Responsible SEO strategy
- Domain analytics
- Competitor organic and paid keyword analytics
- Projects
- Gap analysis
Configured and managed presentations for the Business Development and Executive Management teams, to solidify brand recognition and shape marketing materials.
Designed, developed and maintained website and marketing materials
Designed Salesforce.com applications for RBM and was administrator responsible for maintaining client activities and implementing ad campaigns to track and improve ROI
Rebranded RBM after Myriad acquisition
Responsible for trade show setup including booth and materials